OncoTherics and
University Health Network (UHN), Toronto have signed a memorandum of understanding to progress the
development of the company's novel hypoxia-activated cancer drugs at the Princess Margaret Cancer
Centre (PMCC) - a world class facility
for the detection of tumour hypoxia and the treatment of pancreatic cancer.
Stefan Ogrodzinski (CEO, OncoTherics) said "This is an exciting development for OncoTherics. There is an excellent alignment of interests between the company's novel hypoxia activated prodrug technology and PMCC's expertise in the detection of tumour hypoxia."
No comments:
Post a Comment